Merck: KEYTRUDA Approved By European Commission For Patients With Advanced NSCLC

(RTTNews) - Merck (MRK) announced the European Commission has approved KEYTRUDA (pembrolizumab), the company's anti-PD-1 therapy, at a dose of 2 mg/kg every three weeks, for patients with locally advanced or metastatic non-small cell lung cancer in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. The EC approval allows marketing of KEYTRUDA in all 28 EU member states.

The approval is based on findings from KEYNOTE-010, a study which showed KEYTRUDA significantly improved overall survival compared to standard of care chemotherapy.